TY  - JOUR
AU  - Afshar-Oromieh, Ali
AU  - Avtzi, Eleni
AU  - Giesel, Frederik L
AU  - Holland-Letz, Tim
AU  - Linhart, Heinz G
AU  - Eder, Matthias
AU  - Eisenhut, Michael
AU  - Boxler, Silvan
AU  - Hadaschik, Boris A
AU  - Kratochwil, Clemens
AU  - Weichert, Wilko
AU  - Kopka, Klaus
AU  - Debus, Jürgen
AU  - Haberkorn, Uwe
TI  - The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer.
JO  - European journal of nuclear medicine and molecular imaging
VL  - 42
IS  - 2
SN  - 1619-7089
CY  - Heidelberg [u.a.]
PB  - Springer-Verl.
M1  - DKFZ-2017-02132
SP  - 197 - 209
PY  - 2015
AB  - Since the introduction of positron emission tomography (PET) imaging with (68)Ga-PSMA-HBED-CC (=(68)Ga-DKFZ-PSMA-11), this method has been regarded as a significant step forward in the diagnosis of recurrent prostate cancer (PCa). However, published data exist for small patient cohorts only. The aim of this evaluation was to analyse the diagnostic value of (68)Ga-PSMA-ligand PET/CT in a large cohort and the influence of several possibly interacting variables.We performed a retrospective analysis in 319 patients who underwent (68)Ga-PSMA-ligand PET/CT from 2011 to 2014. Potential influences of several factors such as prostate-specific antigen (PSA) level and doubling time (DT), Gleason score (GSC), androgen deprivation therapy (ADT), age and amount of injected tracer were evaluated. Histological verification was performed in 42 patients after the (68)Ga-PSMA-ligand PET/CT. Tracer uptake was measured in 901 representative tumour lesions.In 82.8
KW  - Glu-NH-CO-NH-Lys-(Ahx)-((68)Ga(HBED-CC)) (NLM Chemicals)
KW  - Oligopeptides (NLM Chemicals)
KW  - Radiopharmaceuticals (NLM Chemicals)
KW  - Edetic Acid (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:25411132
C2  - pmc:PMC4315487
DO  - DOI:10.1007/s00259-014-2949-6
UR  - https://inrepo02.dkfz.de/record/126017
ER  -